The BIOSECURE bill, which aims to prevent US drug companies from outsourcing tasks to Chinese companies, has sparked concern among American pharmaceutical firms. If passed, the bill could potentially impact the healthcare sector, with repercussions felt by customers of Chinese firms.
For big Western drug companies, replacing Chinese capacity would be a challenging and costly endeavor, taking at least five years. This could pose a significant challenge for biotech startups that rely on Chinese partners for research and manufacturing. The bill could effectively put an end to the development of new drugs for these startups.
The debate surrounding national security arguments is complex and multifaceted. While some argue that weakening China reduces the likelihood of war by diminishing the power of the adversary, others contend that it increases the risk of war due to wealthy countries having more to lose. The effectiveness of nationalism in comparison to internationalism remains a contentious issue.
